Atossa Therapeutics reports Q3 2024 results, highlights positive Phase 2 data for (Z)-endoxifen

ATOSSA THERAPEUTICS, INC.

2024-Q3 EPS reported -$0.15

Announced positive topline from KARISMA-Endoxifen Phase 2: MBD reductions of 19.3% (1 mg) and 26.5% (2 mg) vs placebo.
Preliminary I-SPY 2 EOP analysis: 95% (19/20) of patients met primary endpoint with >75% treatment completion.
First patient dosed in combination trial of (Z)-endoxifen with abemaciclib (VERZENIO) in ER+/HER2- breast cancer.
Ended Q3 2024 with $74.8 million cash and equivalents, no debt.
Received new U.S. Patent No. 12,071,391 covering (Z)-endoxifen compositions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.